The use of non-TNF targeted biologics in Behçet’s Disease: Real-life data from the International AIDA Network Behçet’s Disease Registry

Biologics targeting IL-1, IL-6, IL-17, and IL-12/23 pathways may offer therapeutic alternatives in BD patients unresponsive to TNF-α inhibitors. The treatment efficacy varies across phenotypes, highlighting the need for individualized treatment decisions.